The effect of synbiotic in hospitalized covid-19 patients

Phase 3

Recruiting

• Conditions: COVID-19.; U07.1 COVID-19, virus identified; U07.1

• Registration Number: IRCT20210531051459N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Hospitalized patients with definitive diagnosis of Covid 19 using PCR or CT scan
Conscious consent to participate in the study
Age category 18 years and above

Exclusion Criteria

Acute pancreatitis
Pregnancy and lactation
Having autoimmune diseases and taking immunosuppressants or drugs used to reject transplants
Taking supplements containing probiotics and prebiotics in the last three months
Hospitalization in the ICU
Patients treated with herbal medicines or other traditional medicine methods
Dialysis patients
Having a history of allergies to synbiotics
Dissatisfaction with participating in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The level of CRP inflammatory marker. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: Blood test.;The level of IL-6 inflammatory cytokine. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: ELISA.;ESR level. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: Blood test.